<DOC>
	<DOC>NCT01326689</DOC>
	<brief_summary>This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose titration in treating breakthrough pain episodes in adult cancer patients receiving strong opioid analgesic on a fixed-schedule as well as rescue medication for breakthrough pain.</brief_summary>
	<brief_title>A Comparative Study of KW-2246</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<criteria>Written informed consent Have been treated with opioid analgesic on a fixedschedule at a stable daily dose Receiving at least 1 but not more than 4 doses of rescue medication per day in average and whose pain is controlled ECOG PS =&lt; 3 Currently suffered from intolerable opioidspecific adverse reactions due to opioid analgesics Severe respiratory dysfunction Asthma Severe bradyarrhythmia Severe hepatic function disorder Severe renal function disorder Severe psychoneurotic disorder Susceptibility to respiratory depression due to such conditions as increased intracranial pressure, head injury or brain tumor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>